Pfizer (NYSE:PFE) and its German partner BioNTech (NASDAQ: BNTX) will proceed with a COVID-19 vaccine trial involving as many as 4,500 children. The trial will significantly reduce the 30-mg dose that adults and adolescents receive. Investigators will administer a 10-µg dose to children aged 5 to 11 and give those aged six months to five years old a 3-µg dose.
The company anticipates data from 5- to 11-year-olds in September and plans on filing for emergency use authorization shortly after that.
The company anticipates that data for the 6-month to 2-year-old cohort will be available in October or November.
Get the full story from our sister site, Drug Discovery & Development.